[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370465-105":59,"doc-detail-370465-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cancer-and-overgrowth-manifestations-of-pten-hamartoma-tumor-syndrome-management-recommendations-from-the-international-phts-consensus-guidelines-working-group","Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group","","Purpose: PTEN hamartoma tumor syndrome (PHTS) is an autosomal dominant cancer predisposition and overgrowth condition driven by pathogenic germline PTEN variants, increasing risk for benign and malignant tumors across breast, colon, endometrium, thyroid, skin, and kidney. Objective: develop an international consensus resource using latest knowledge to guide surveillance and management for providers, researchers, and affected individuals. Experimental design: an expert working group met regularly between 2022 and 2024 and used an iterative modified Delphi approach with an external expert panel. Results: consensus recommendations for surveillance and management. Conclusions: complex care requires a multidisciplinary approach and aims to improve outcomes for patients and families.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-and-overgrowth-manifestations-of-pten-hamartoma-tumor-syndrome-management-recommendations-from-the-international-phts-consensus-guidelines-working-group/370465/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-and-overgrowth-manifestations-of-pten-hamartoma-tumor-syndrome-management-recommendations-from-the-international-phts-consensus-guidelines-working-group/370465.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is PTEN hamartoma tumor syndrome (PHTS) and what risks does it increase?","Question",{"text":113,"@type":114},"PHTS is an autosomal dominant cancer predisposition and overgrowth syndrome caused by pathogenic germline PTEN variants. It increases risk for both benign and malignant tumors involving breast, colon, endometrium, thyroid, skin, and kidney.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the international consensus guidelines developed?",{"text":118,"@type":114},"The International PHTS Cancer and Overgrowth Guidelines Working Group included core international experts and met with individuals with PHTS and advocates. Guideline statements were refined between 2022 and 2024 using an iterative modified Delphi approach with an external expert panel.",{"name":120,"@type":111,"acceptedAnswer":121},"What do the guidelines cover for surveillance and management?",{"text":122,"@type":114},"The guidelines provide consensus recommendations for surveillance and management of cancer and overgrowth in individuals with PHTS. They address recommended practices for breast, colon, endometrial, thyroid, and kidney cancers, as well as overgrowths.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370465,1790227568,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group  \nAndrew Dhawan1,2, Sarah Baitamouni2, Darren Liu2,3, Lamis Yehia2, Kristin Anthony4, Alicia McCarther4, Marc Tischkowitz5, Suzanne P. MacFarland6, Joanne Ngeow7,8, Nicoline Hoogerbrugge9, and Charis Eng2,10,11,12,†  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: PTEN hamartoma tumor syndrome (PHTS) is an autosomal dominant cancer predisposition and overgrowth syndrome caused by pathogenic germline variants in the PTEN gene, with an increased risk of both benign and malignant tumors involving the breast, colon, endometrium, thyroid, skin, and kidney. The objective of these clinical guidelines was to use the latest knowledge to generate an international consensus resource for providers, researchers, and individuals with PHTS on the best practices in the surveillance and management of cancer andovergrowth in PHTS.\u003Cbr>Experimental Design: The International PHTS Cancer and Overgrowth Guidelines Working Group was established, comprising a core group of six international experts in the diagnosis and management of PHTS. The working group held joint meetings with individuals with PHTS and their advocates. Informed by the literature, the working group met\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | regularly between 2022 and 2024 to produce guideline statements, refined through iterative feedback. A modified Delphi approach was used with an independent external panel of PHTS, genetics, and cancer experts to establish final consensus guidelines.\u003Cbr>Results: Clinical consensus recommendations for the surveillance and management of cancer and overgrowth in individuals with PHTS were formed. The guidelines encompass the recommended practices in cases of breast, colon, endometrial, thyroid, and kidney cancers, as well as overgrowths.\u003Cbr>Conclusions: The clinical management of individuals with PHTS is complex and necessitates a multidisciplinary approach. We generated international consensus guidelines for the surveillance and management of cancer and overgrowth in PHTS, aiming at improving care for affected individuals and families. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\n1Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio. 2Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. 3Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 4PTEN Hamartoma Tumor Syndrome Foundation, Huntsville, Alabama. 5Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom. 6Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylva","cbCaiiEay5eaH1Lz","https://ap.wps.com/l/cbCaiiEay5eaH1Lz","pdf",1765400,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is PTEN hamartoma tumor syndrome (PHTS) and what risks does it increase?\",\"answer\":\"PHTS is an autosomal dominant cancer predisposition and overgrowth syndrome caused by pathogenic germline PTEN variants. It increases risk for both benign and malignant tumors involving breast, colon, endometrium, thyroid, skin, and kidney.\"},{\"question\":\"How were the international consensus guidelines developed?\",\"answer\":\"The International PHTS Cancer and Overgrowth Guidelines Working Group included core international experts and met with individuals with PHTS and advocates. Guideline statements were refined between 2022 and 2024 using an iterative modified Delphi approach with an external expert panel.\"},{\"question\":\"What do the guidelines cover for surveillance and management?\",\"answer\":\"The guidelines provide consensus recommendations for surveillance and management of cancer and overgrowth in individuals with PHTS. They address recommended practices for breast, colon, endometrial, thyroid, and kidney cancers, as well as overgrowths.\"}]","Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group | PDF",1790188677]